認知症診療ガイドライン2017_800_第8章.indd
|
|
|
- きみえ たかひ
- 5 years ago
- Views:
Transcription
1 8CQ 8 frontotemporal lobar degeneration FTLD Pick Alzheimer FTLD Alzheimer FTLD frontotemporal dementia FTD FTLD FTLD FTLD behavioral variant frontotemporal dementia bvftd semantic dementia SD Sylvius progressive non fluent aphasia PNFA 3 1FTD bvftd SD PNFA CQ FTLD frontotemporal dementia and motor neuron disease FTD MND TAR DNA binding protein of 43kD TDP 43fused in sarcoma FUS C 3 4 FTLD FTLD tau FTLD tau 3 Pick 4 TDP 43 FUS RNA FTLD TDP 43 FUS FTLD TDP FTLD FUS CQ
2 3 2 bvftd FTLD TDP PNFA 70% FTLD tau PSP CBD Pick SD 80% FTLD TDP CQ MRI CT SPECT 30 50% 行動障害型前頭側頭型認知症 behavioral variant FTD bvftd 前頭側頭葉変性症 frontotemporal lobar degeneration FTLD 意味性認知症 semantic dementia SD 進行性非流暢性失語症 progressive non fluent aphasia PNFA 1FTLD 前頭側頭葉変性症 (FTLD) タウオパチー (FTLD tau) タウ陰性 FTLD 3R tau 4R tau 3R & 4R tau TDP 43 陽性 TDP 43 陰性 ピック病 CBD PSP AGD GGT FTDP 17 with 4R tau NFT dementia FTDP 17 with 3R & 4R tau FTLD TDP ユビキチン陽性 FTLD FUS (NIFID, BIBD, aftld U) FTLD UPS with CHMP2B mutation ユビキチン陰性 DLDH 2FTLD 3R 3 4R 4 CBD 変性症 PSP 進行性 性 AGD 性認知症 GGT FTDP 前頭側頭型認知症 NFT dementia 変 型 認知症 NIFID 性 BIBD 性 aftld U 非 型 FTLD CHMP2B mutation 2B CHMP2B 変 DLDH 認知症 Lashley T, Rohrer JD, Mead S, et al. Review An update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Neuropathol Appl Neurobiol
3 8CQ FTLD の臨床病型 FTLD の臨床病型に応じた病理学的所見の 0 違いに関するおよその比率 100 bvftd PNFA SD PSP CBD Pick 病 TDP 43 Type A TDP 43 Type B TDP 43 Type C 3 D Alton S, Lewis J. Therapeutic and diagnostic challenges for frontotemporal dementia. Front Aging Neurosci TARDBP FUS C9orf FTLD 1 Lashley T, Rohrer JD, Mead S, et al. Review An update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Neuropathol Appl Neurobiol D Alton S, Lewis J. Therapeutic and diagnostic challenges for frontotemporal dementia. Front Aging Neurosci
4 CQ 8 1 frontotemporal lobar degenera tion FTLD FTLD behavioral variant fron totemporal dementia bvftd 2011 International Behavioural Variant FTD Criteria Consortium FTDC semantic dementia SD B FTLD bvftd SD progressive non fluent aphasia PNFA264 1 bvftd SD 1. bvftd Rascovsky FTDC 1 1FTDC possible 93% probable 80%possible 90% 2 Harris possible 95% 82% probable 85% 95% 3 Alzheimer Lewy 2 FTDC FTDC κ possible 0.81 probable 0.82 κ κ CQ % tau TARDBP FUS progranulin C9orf Diagnostic and Statistical Manual of Mental Disorders Fifth Edition DSM 5 Dementia Neurocognitive 266 8
5 8CQ 8 1 Disorder NCDFTLD major or mild Frontotemporal NCD Behavioral variant Language variant FTDC 2. SD Gorno Tempini 5 / CQ SD SD bvftd 2011 Gorno Tempine semantic variant Neary bvftd 1 bvftd A Possible bvftd /A F 3 AA.1 A.3 1 A.1A.2 A.3 BB.1 B.2 1 B.1 B.2 CC.1 C.2 1 C.1 C.2 DD.1 D.3 1 D.1 D.2D.3 E E.1 E.3 1 E.1 E.2 E.3 F F.1 F.3 F.1 F.2F.3 Probable bvftd A C A possible bvftd B Clinical Dementia Rating CDR C bvftd C.1 C.2 1 C.1 MRI/CT C.2 PET/SPECT FTLD bvftd A B C A possible probable bvftd B FTLD C bvftd bvftd A B C possible bvftd probable bvftd A B C Alzheimer Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotem poral dementia. Brain Pt
6 2 1 a 2 A B b / 2 c MRI/CT 5 1 Alzheimer 2 Lewy a b c 3 / / 2 1 a MRI b SPECT PET Gorno Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology
7 8CQ 8 1 SD 2 SD / SD Alzheimer SD 3. PNFA PNFA / Gorno Tempini Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of fronto temporal dementia. Brain Pt Balasa M, Gelpi E, Martín I, et al. Diagnostic accuracy of behavioral variant frontotemporal dementia consortium criteria FTDC in a clinicopathological cohort. Neuropathol Appl Neurobiol Harris JM, Gall C, Thompson JC, et al. Sensitivity and specificity of FTDC criteria for behavioral variant frontotemporal dementia. Neurology Lamarre AK, Rascovsky K, Bostrom A, et al. Interrater reliability of the new criteria for behavioral variant frontotemporal dementia. Neurology Gorno Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration a consensus on clinical diagnostic criteria. Neurology
8 PubMed #1 "Frontotemporal Lobar Degeneration/diagnosis" Mesh OR "frontotemporal lobar degeneration" TI OR "frontotemporal dementia" TI OR FTD TI OR FTLD TI OR bvftd TIAND Dementia/diagnosis Mesh OR "frontotemporal lobar degeneration" OR "frontotemporal dementia" OR FTD OR FTLD bvftd AND diagnosis OR diagnoses OR diagnostic #1 /TH OR /TI OR /TH OR /TI OR "Frontotemporal Lobar Degeneration"/TI OR "Frontotemporal Dementia"/TI OR FTD/TI OR FTLD/TI OR bvftd AND SH,,, X,, OR /TH OR /TI 270 8
9 8CQ 8 2 CQ 8 2 frontotemporal lobar degenera tion FTLD FTLD behavioral variant frontotemporal dementia bvftd MRI/CT SPECT/PET semantic dementia SD MRI/CT SPECT/PET progressive non fluent aphasia PNFA MRI/CT SPECT/PET FTLD 1B 1. MRI/CT SPECT/PET 1 bvftd MRI/CT SPECT/PET SD MRI/CT SPECT/PET PNFA MRI/CT SPEC/PETT 1 bvftd SD MRI bvftd SD FTLD 2. Alzheimer Lewy FTLD 2 bvftd 1 3 SD 271
10 PNFA Broca 3. 4 bvftd SD PNFA 4. MRI 4 bvftd 5. 5 C9orf 72 tau progranulin tau progranulin progranulin C9orf 72 tau 6. 6 FTLD 3 TDP 43 FUS MRI PET 7,8 7. phenocopy syndrome 1 MRI bvftd phenocopy syndrome 行動障害型前頭側頭型認知症 (bvftd) 意味性認知症 (SD) R R 1 MRI 272 8
11 8CQ 8 2 FDG PET 1 Whitwell JL, Josephs KA. Recent advances in the imaging of frontotemporal dementia. Curr Neurol Neurosci Rep Vemuri P, Simon G, Kantarci K, et al. Antemortem differential diagnosis of dementia pathology using structural MRI Differential STAND. Neuroimage Pan PL, Song W, Yang J, et al. Gray matter atrophy in behavioral variant frontotemporal dementia a meta analysis of voxel based morphometry studies. Dement Geriatr Cogn Disord Risacher SL, Saykin AJ. Neuroimaging biomarkers of neurodegenerative diseases and dementia. Semin Neurol Whitwell JL, Weigand SD, Boeve BF, et al. Neuroimaging signatures of frontotemporal dementia genetics C9ORF72, tau, progranulin and sporadics. Brain Pt Whitwell JL, Josephs KA. Neuroimaging in frontotemporal lobar degeneration predicting molecular pathology. Nat Rev Neurol Maruyama M, Shimada H, Suhara T, Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron Okamura N, Furumoto S, Fodero Tavoletti MT, et al. Non invasive assessment of Alzheimer s disease neurofibrillary pathology using 18F THK5105 PET. Brain Pt PubMed #1 "Frontotemporal Lobar Degeneration/diagnosis" Mesh OR "frontotemporal lobar degeneration" TI OR "frontotemporal dementia" TI OR FTD TI OR FTLD TI OR bvftd TI AND "Dementia/diagnosis" MeshOR "frontotemporal lobar degeneration" OR "frontotemporal dementia" OR FTD OR FTLD bvftd AND diagnosis OR diagnoses OR diagnostic AND "Diagnostic Imaging" Mesh OR "magnetic resonance imaging" OR "single photon emission computed tomography" OR "positron emission tomography" OR MRI OR SPECT OR PET #1 /TH OR /TI OR /TH OR /TI OR "Frontotemporal Lobar Degeneration"/TI OR "Frontotemporal Dementia"/TI OR FTD/TI OR FTLD/TI OR bvftd AND SH,,, X,, OR /TH OR /TI AND /TH OR MRI/TI OR OR OR OR OR PET/TI OR OR OR SPECT/TI OR OR OR OR OR 273
12 CQ 8 3 frontotemporal lobar degenera tion FTLD FTLD selective serotonin reuptake inhibitor SSRI 2C FTLD 1,2 Nardell 2 Mini Mental State Examination MMSE FTLD SSRI 3 FTLD SSRI 1997 Swartz 4 FTLD SSRI 5 FTLD SSRI Lanctôt PET 4 FTLD 10 5 HT 1A 6 Hughes SSRI FTLD 7 cholinesterase inhibitor ChEI 1,2 ChEI ChEI FTLD ChEI 8 NMDA 3 FTLD 2 RCT 24 Neuropsychiatric Inventory NPI 9 10 FTLD TDP 43 FUS
13 8CQ Riedl L, Mackenzie IR, Förstl H, et al. Frontotemporal lobar degeneration current perspectives. Neuropsychiatr Dis Treat Nardell M, Tampi RR. Pharmacological treatments for frontotemporal dementias a systematic review of randomized controlled trials. Am J Alzheimers Dis Other Demen Lebert F, Stekke W, Hasenbroekx C, et al. Frontotemporal dementia a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord Swartz JR, Miller BL, Lesser IM, et al. Frontotemporal dementia treatment response to serotonin selective reuptake inhib itors. J Clin Psychiatry Ikeda M, Shigenobu K, Fukuhara R, et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotem poral lobar degeneration patients. Dement Geriatr Cogn Disord Lanctôt KL, Herrmann N, Ganjavi H, et al. Serotonin 1A receptors in frontotemporal dementia compared with controls. Psychiatry Res Hughes LE, Rittman T, Regenthal R, et al. Improving response inhibition systems in frontotemporal dementia with citalo pram. Brain Pt Li Y, Hai S, Zhou Y, et al. Cholinesterase inhibitors for rarer dementias associated with neurological conditions. Cochrane Database Syst Rev CD Jesso S, Morlog D, Ross S, et al. The effects of oxytocin on social cognition and behaviour in frontotemporal dementia. Brain Pt Finger EC, MacKinley J, Blair M, et al. Oxytocin for frontotemporal dementia a randomized dose finding study of safety and tolerability. Neurology PubMed #1 "Frontotemporal Lobar Degeneration/drug therapy" Mesh OR "frontotemporal lobar degeneration" TI OR "frontotemporal dementia" TI OR FTD TI OR FTLD TI OR bvftd TI AND Dementia/drug therapy MeshOR "frontotemporal lobar degeneration" OR "frontotemporal dementia" OR FTD OR FTLD bvftd AND "drug therapy" OR chemotherapy OR pharmacotherapy OR "pharmacological therapy" #1 /TH OR /TI OR /TH OR /TI OR "Frontotemporal Lobar Degeneration"/TI OR "Frontotemporal Dementia"/TI OR FTD/TI OR FTLD/TI OR bvftd AND SHOR /MTH OR /MTH OR /TI OR /TI OR /TI 275
14 CQ 8 4 frontotemporal lobar degenera tion FTLD FTLD 2C FTLD 1 Alzheimer FTLD 2 Shinagawa 3 6 FTLD quality of life QOL 4 Mioshi 5 McKinnon Lough 1 FTLD 8 1 FTLD 9 2 FTLD 5 Alzheimer Alzheimer FTLD activities of daily living ADL 10 7,9,
15 8CQ Bozeat S, Gregory CA, Ralph MA, et al. Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer s disease? J Neurol Neurosurg Psychiatry Merrilees J. A model for management of behavioral symptoms in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord S64 S69. 3 Shinagawa S, Nakajima S, Plitman E, et al. Non pharmacological management for patients with frontotemporal dementia a systematic review. J Alzheimers Dis Pick Mioshi E, McKinnon C, Savage S, et al. Improving burden and coping skills in frontotemporal dementia caregivers A pilot study. Alzheimer Dis Assoc Disord McKinnon C, O Connor CM, Savage S, et al. Qualitative results of a structured group program for carers of people with frontotemporal dementia. Int J Geriatr Psychiatry Pick Lough S, Hodges JR. Measuring and modifying abnormal social cognition in frontal variant frontotemporal dementia. J Psychosom Res Yokota O, Fujisawa Y, Takahashi J, et al. Effects of group home care on behavioral symptoms, quality of life, and psycho tropic drug use in patients with frontotemporal dementia. J Am Med Dir Assoc PubMed #1 "Frontotemporal Lobar Degeneration/therapy" Mesh OR "Frontotemporal Lobar Degeneration" Majr AND "Therapeutics" MeshOR "frontotemporal lobar degeneration" TI OR "frontotemporal dementia" TI OR FTD TI OR FTLD TI OR bvftd TI OR pick disease* TI OR picks disease* TI OR "frontal lobe dementia" TI OR "frontotemporal lobe dementia" TI OR "frontal variant frontotemporal dementia" TIAND Dementia/therapy Mesh OR "frontotemporal lobar degeneration" OR "frontotemporal dementia" OR FTD OR FTLD OR bvftd OR pick disease* OR picks disease* OR "frontal lobe dementia" OR "frontotemporal lobe dementia" OR "frontal variant frontotemporal dementia" AND therapy OR therapeutic OR treatment OR intervention* NOT "Frontotemporal Lobar Degeneration/drug therapy" Mesh OR "Frontotemporal Lobar Degeneration" Majr AND "Drug Therapy" Mesh OR "frontotemporal lobar degeneration" TI OR "frontotemporal dementia" TI OR FTD TI OR FTLD TI OR bvftd TI OR pick disease* TI OR picks disease* TI OR "frontal lobe dementia" TI OR "frontotemporal lobe dementia" TI OR "frontal variant frontotemporal dementia" TIAND Dementia/drug therapy Mesh OR "frontotemporal lobar degeneration" OR "frontotemporal dementia" OR FTD OR FTLD OR bvftd OR pick disease* OR picks disease* OR "frontal lobe dementia" OR "frontotemporal lobe dementia" OR "frontal variant frontotemporal dementia" AND "drug therapy" OR chemotherapy OR pharmacotherapy OR "pharmacological therapy" OR "nonpharmacological therapy" OR "non pharmacological therapy" OR "nonpharmacologic therapy" OR "non pharmacologic therapy" OR "nonpharmacological treatment" OR "non pharmacological treatment" OR "nonpharmacologic treatment" OR "non pharmacologic treatment" OR nonpharmacological intervention* OR non pharmacological intervention* OR nonpharmacologic intervention* OR non pharmacologic intervention* OR "nonpharmacological management" OR "non pharmacological management" OR "nonpharmacologic management" OR "non pharmacologic management" AND "Frontotemporal Lobar Degeneration" Mesh OR "frontotemporal lobar degeneration" OR "frontotemporal dementia" OR FTD OR FTLD OR bvftd OR pick disease* OR picks disease* OR "frontal lobe dementia" OR "frontotemporal lobe dementia" OR "frontal variant frontotemporal dementia" OR "Frontotemporal Lobar Degeneration/rehabilitation" Mesh OR "Frontotemporal Lobar Degeneration/therapy" Mesh AND "Rehabilitation" Mesh OR "frontotemporal lobar degeneration" TI OR "frontotemporal dementia" TI OR FTD TI OR FTLD TI OR bvftd TI OR pick disease* TI OR picks disease* TI OR "frontal lobe dementia" TI OR "frontotemporal lobe dementia" TI OR "frontal variant frontotemporal dementia" TI AND rehabilitation TI OR "occupational therapy" TI OR "activities of daily living" TI OR "activity of daily living" TI OR "frontotemporal lobar degeneration" OR "frontotemporal dementia" OR FTD OR FTLD OR bvftd OR pick disease* OR picks disease* OR "frontal lobe dementia" OR "frontotemporal lobe dementia" OR "frontal variant frontotemporal dementia" AND rehabilitation OR "occupational therapy" OR "activities of daily living" OR "activity of daily living"or "Frontotemporal Lobar Degeneration/nursing" Mesh OR "Frontotemporal Lobar Degeneration/ therapy" Mesh AND "Nursing" Mesh OR "frontotemporal lobar degeneration" TI OR "frontotemporal 277
16 dementia" TI OR FTD TI OR FTLD TI OR bvftd TI OR pick disease* TI OR picks disease* TI OR "frontal lobe dementia" TI OR "frontotemporal lobe dementia" TI OR "frontal variant frontotemporal dementia" TI AND nursing TI OR "frontotemporal lobar degeneration" OR "frontotemporal dementia" OR FTD OR FTLD OR bvftd OR pick disease* OR picks disease* OR "frontal lobe dementia" OR "frontotemporal lobe dementia" OR "frontal variant frontotemporal dementia" AND nursing OR "Frontotemporal Lobar Degeneration/diet therapy" Mesh OR "Frontotemporal Lobar Degeneration/therapy" Mesh AND "Nutrition Therapy" Mesh OR "frontotemporal lobar degeneration" TI OR "frontotemporal dementia" TI OR FTD TI OR FTLD TI OR bvftd TI OR pick disease* TI OR picks disease* TI OR "frontal lobe dementia" TI OR "frontotemporal lobe dementia" TI OR "frontal variant frontotemporal dementia" TI AND nutrition therap* TI OR diet therap* TI OR "frontotemporal lobar degeneration" OR "frontotemporal dementia" OR FTD OR FTLD OR bvftd OR pick disease* OR picks disease* OR "frontal lobe dementia" OR "frontotemporal lobe dementia" OR "frontal variant frontotemporal dementia" AND nutrition therap* OR diet therap* OR "Frontotemporal Lobar Degeneration/ surgery" Mesh OR "Frontotemporal Lobar Degeneration/therapy" Mesh AND "Surgical Procedures, Operative" Mesh OR "frontotemporal lobar degeneration" TI OR "frontotemporal dementia" TI OR FTD TI OR FTLD TI OR bvftd TI OR pick disease* TI OR picks disease* TI OR "frontal lobe dementia" TI OR "frontotemporal lobe dementia" TI OR "frontal variant frontotemporal dementia" TI AND surgery TI OR surgical TI OR operation TI OR operative TI OR "frontotemporal lobar degeneration" OR "frontotemporal dementia" OR FTD OR FTLD OR bvftd OR pick disease* OR picks disease* OR "frontal lobe dementia" OR "frontotemporal lobe dementia" OR "frontal variant frontotemporal dementia" AND surgery OR surgical OR operation OR operative OR "Frontotemporal Lobar Degeneration/radiotherapy" Mesh OR "Frontotemporal Lobar Degeneration/therapy" Mesh AND "Radiotherapy" Mesh OR "frontotemporal lobar degeneration" TI OR "frontotemporal dementia" TI OR FTD TI OR FTLD TI OR bvftd TI OR pick disease* TI OR picks disease* TI OR "frontal lobe dementia" TI OR "frontotemporal lobe dementia" TI OR "frontal variant frontotemporal dementia" TI AND radiotherap* TI OR chemoradiotherap* TI OR radiosurg* TI OR "frontotemporal lobar degeneration" OR "frontotemporal dementia" OR FTD OR FTLD OR bvftd OR pick disease* OR picks disease* OR "frontal lobe dementia" OR "frontotemporal lobe dementia" OR "frontal variant frontotemporal dementia" AND radiotherap* OR chemoradiotherap* OR radiosurg* OR "Frontotemporal Lobar Degeneration/therapy" Mesh AND "Psychotherapy" Mesh OR "frontotemporal lobar degeneration" TI OR "frontotemporal dementia" TI OR FTD TI OR FTLD TI OR bvftd TI OR pick disease* TI OR picks disease* TI OR "frontal lobe dementia" TI OR "frontotemporal lobe dementia" TI OR "frontal variant frontotemporal dementia" TI AND psychotherap* TI OR "frontotemporal lobar degeneration" OR "frontotemporal dementia" OR FTD OR FTLD OR bvftd OR pick disease* OR picks disease* OR "frontal lobe dementia" OR "frontotemporal lobe dementia" OR "frontal variant frontotemporal dementia" AND psychotherap* OR "Frontotemporal Lobar Degeneration/therapy" Mesh AND "Patient Care" Mesh OR "frontotemporal lobar degeneration" TI OR "frontotemporal dementia" TI OR FTD TI OR FTLD TI OR bvftd TI OR pick disease* TI OR picks disease* TI OR "frontal lobe dementia" TI OR "frontotemporal lobe dementia" TI OR "frontal variant frontotemporal dementia" TI AND care TI OR cares TI OR "frontotemporal lobar degeneration" OR "frontotemporal dementia" OR FTD OR FTLD OR bvftd OR pick disease* OR picks disease* OR "frontal lobe dementia" OR "frontotemporal lobe dementia" OR "frontal variant frontotemporal dementia" AND care OR cares #1 /TH OR /TI OR /TH OR /TI OR "Frontotemporal Lobar Degeneration"/TI OR "Frontotemporal Dementia"/TI OR FTD/TI OR FTLD/TI OR bvftd OR /TI OR Pick OR /TI OR /TI OR /TI AND SH,,,,,,,,, OR /MTH OR /TI OR /TINOT /TH OR /TI OR /TH OR /TI OR "Frontotemporal Lobar Degeneration"/TI OR "Frontotemporal Dementia"/TI OR FTD/TI OR FTLD/TI OR bvftd OR /TI OR Pick OR /TI OR /TI OR /TI AND SHOR /TH OR /MTH OR /TI OR /TI OR /TI OR /TH OR /TI OR /TH OR /TI OR "Frontotemporal Lobar Degeneration"/TI OR "Frontotemporal Dementia"/TI OR FTD/TI OR FTLD/TI OR bvftd OR /TI OR Pick OR /TI OR /TI OR /TI AND SH,,,,,, OR /TI OR /TI OR /MTH OR /TI OR /MTH OR /TI OR /MTH OR /TI OR /TI OR /TI OR /MTH OR /TI OR /TI OR /TI OR /TI OR /TH OR /TI OR /TI OR /TI OR /MTH OR /TI OR /TI 278 8
17 8CQ 8 5 CQ 8 5 frontotemporal lobar degenera tion FTLD FTLD 2C FTLD Alzheimer 1 3 FTLD Alzheimer FTLD Kumamoto 2 FTLD 7 8 Nunnemann FTLD FTLD 9 1 Bozeat S, Gregory CA, Ralph MA, et al. Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer s disease? J Neurol Neurosurg Psychiatry Bathgate D, Snowden JS, Varma A, et al. Behaviour in frontotemporal dementia, Alzheimer s disease and vascular dementia. Acta Neurol Scand Ikeda M, Brown J, Holland AJ, et al. Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer s disease. J Neurol Neurosurg Psychiatry Suppl de Vugt ME, Riedijk SR, Aalten P, et al. Impact of behavioural problems on spousal caregivers a comparison between Alzheimer s disease and frontotemporal dementia. Dement Geriatr Cogn Disord Boutoleau Bretonnière C, Vercelletto M, Volteau C, et al. Zarit burden inventory and activities of daily living in the behav 279
18 ioral variant of frontotemporal dementia. Dement Geriatr Cogn Disord Kumamoto K, Arai Y, Hashimoto N, et al. Problems family caregivers encounter in home care of patients with frontotem poral lobar degeneration. Psychogeriatrics MED REHABIL Nunnemann S, Kurz A, Leucht S, et al. Caregivers of patients with frontotemporal lobar degeneration a review of burden, problems, needs, and interventions. Int Psychogeriatr PubMed #1 "Frontotemporal Lobar Degeneration" Majr OR "frontotemporal lobar degeneration" TI OR "frontotemporal dementia" TI OR FTD TI OR FTLD TI OR bvftd TI OR pick disease* TI OR picks disease* TI OR "frontal lobe dementia" TI OR "frontotemporal lobe dementia" TI OR "frontal variant frontotemporal dementia" TIAND care OR education OR burden OR support* AND caregiver* OR family #1 /TH OR /TI OR /TH OR /TI OR "Frontotemporal Lobar Degeneration"/TI OR "Frontotemporal Dementia"/TI OR FTD/TI OR FTLD/TI OR bvftd OR /TI OR Pick OR /TI OR /TI OR /TI AND /TH OR OR /TH OR AND /TH OR OR /TH OR OR OR OR 280 8
FTD off - label 79 FTD Boxer et al., 2012b Alzheimer s disease : AD Cholinesterase inhibitor : ChEI FTD FTD Mendez et al., 2007 FTD Kerssens et al., 2
78 Dementia Japan 29 : 78-85, 78 2015 原著 要旨 4 FTD 87 6 2 1/3 Off - label medication for frontotemporal dementia in Japan Shunichiro Shinagawa 1, Yusuke Yatabe 2, Kazue Shigenobu 3, Ryuji Fukuhara 2, Mamoru
第 8 章 前 頭 側 頭 型 認 知 症 317 はこれらを 認 めない 例 も 含 まれている. 運 動 ニューロン 疾 患 型 は 本 邦 を 中 心 に 報 告 されて きた 認 知 症 を 伴 う 運 動 ニューロン 疾 患 ( 湯 浅 三 山 型 ) にほぼ 相 当 し, 脊 髄 や 大
316 第 8 章 前 頭 側 頭 型 認 知 症 CQ 8-1 前 頭 側 頭 型 認 知 症 frontotemporal dementia(ftd)と 前 頭 側 頭 葉 変 性 症 frontotemporal lobar degeneration(ftld)との 相 違 点 は 推 奨 FTD と FTLD はしばしば 同 義 語 として 使 用 される 場 合 があるが,FTD は FTLD
Vol.19 No FTD 3 Pick 2 3 frontal lobe degeneration: FLDPick Pick FLD MND FLD 図 1 3) Frontotemporal lobar degeneration(ftld) 概念の台頭と定着 FTD progre
Frontotemporal lobar degeneration 変遷する病理学的概念と定型的臨床徴候 Frontotemporal lobar degeneration: ever evolving pathological concepts and typical clinical presentations 昭和大学横浜市北部病院内科 / 准教授 ( 神経内科担当 ) * はじめに Frontotemporal
プログラム_指定演題.indd
400 Dementia Japan Vol. 27 No. 4 October 2013 11 9 13 45 14 15 1 : 11 9 14 15 15 15 1 : β β Jorge A Ghiso Departments of Pathology and Psychiatry, New York University School of Medicine, New York, USA
Diagnosis of Dementia: Update
10 C A 1 2 Normal SMI MCI Early Dementia B Moderate Dementia 3 Severe Dementia 4 5 D AD, VD, FTD, DLB, PDD Depression Dementia d/t GMC Modifiable risk factors and preventive factors for dementia 6-5 -
606 Dementia Japan Vol. 29 No. 4 October 2015 Table 1. The day care for people with severe dementia Outline Subjects Personal distribution Medical man
Dementia Japan 29 : 605-614, 2015 605 原著 要旨 1. はじめに 1 26 4.2 80 2 3 A survey of daycare facilities for dementia people in Japan Tohmi Osaki, Kiyoshi Maeda 1 650-0017 7-5 - 2 Medical Center for Dementia,
認知症診療ガイドライン2017_300_第3章.indd
3 A CQ 3A 1 quality of life QOL post diagnostic support post diagnostic support 1 2 1 2 QOL 3 4 5 post diagnostic support 54 3 3 1 Innes A, Szymczynska P, Stark C. Dementia diagnosis and post diagnostic
82 CQ2 医療機関受診時にけいれん発作が続いている場合, 最初に試みるべき治療は何か 1 PubMed #1 Status Epilepticus/therapy Majr OR status epilepticus TI AND therap TIAB OR treatment TIAB NO
81 文献検索式 CQ1 CQ14 CQ1 CQ1 けいれん発作に対して重積化を防ぐために早期に治療介入することは必要か 1 PubMed 1980 1 2015 12 2016 4 30 #1 Status Epilepticus/therapy Majr OR status epilepticus TI AND therap TIAB OR treatment TIAB OR prevent TIAB
untitled
Ⅷ 184 Ⅰ 定義, 概要, 経過, 疫学 Ⅱ 診断 Ⅲ 治療原則, 選択肢 Ⅳ 経過, 治療計画 ⅤAD Ⅵ VaD CQ Ⅷ-1 frontotemporal dementia(ftd) と前頭側頭葉変性症 frontotemporal lobar degeneration(ftld) との相違点は 推奨 FTD と FTLD はしばしば同義語として使用される場合があるが, FTD は FTLD
認知症治療薬の考え方，使い方
Ch a pterⅠ 1 はじめに わが国における高齢者の認知症有病率は今後も高くなり 認知症者が増 加していく可能性が示されている1,2 海外においても アジア アフリカ などを中心に今後の認知症者数が増大する可能性が指摘されている 一 方 欧米においては認知症者発症率の減少を指摘する報告もある しかし 高齢化もあって認知症者数は増加すると考えられ わが国のみならず世界 の認知症者数は増加すると考えられている
BPSD A 群 B 群 A 群 B 群 妄想幻覚興奮うつ不安 n mean S.D. p-value n mean S.D. p-value 0 週 p= p= 週 週
BPSD の治療 Pharmacotherapy for BPSD 筑波大学大学院人間総合科学研究科精神病態医学分野 / 准教授 * 1. はじめに 8 Behavioral psychological symptoms of dementia BPSD 図 1BPSD BPSD BPSD BPSD 2. 興奮 攻撃性の治療 2005 図 2 DLB K BPSD 図 3 心理症状 幻覚 ( 幻視
認知症診療ガイドライン2017_100_第1章.indd
1 CQ 1 1 10 ICD 10 /Alzheimer National Institute on Aging Alz heimer s Association workgroup NIA AA 5 DSM 5 ICD 10 1993 1 1 NIA AA 2011 Alzheimer 2 2 DSM 5 2013 neurocognitive disorders dementia major
medicaljournal8.pdf
Medical Journal of Aizawa Hospital Vol. 8 (2010) Key words Neuropsychopharmacology Neuroscientist Curr Opin Neurol Clin Rehabil J Neurol Neurosurg Psychiatry J Neurol Neurosurg Psychiatry Lancet
56: Hands-on 4 Meet the Expert.
56:136 57 2016 28 5 18 21. 650-0046 6-9-1 650-0046 6-11-1 650-0046 6 10-1 2016 2 9 7 13 Hands-on 4 Meet the Expert. http://www.neurology-jp.org/sokaitiho/neuro2016/ 15,000 18,000 3,000 3,000 3,000 3,000
Medical Journal of Aizawa Hospital Medical Journal of Aizawa Hospital Vol. 8 (2010) Key words Neuropsychopharmacology Neuroscientist Curr Opin Neurol Clin Rehabil J Neurol Neurosurg Psychiatry
118 Dementia Japan Vol. 31 No. 1 January 2017 表 1. DLB に対して mect を行った先行研究 Rasmussen K 2003 USA Japan Japan Japan Japan 1 2
Dementia Japan 31 : 117-124, 2017 117 症例報告 要旨 1. はじめに 70 1 modified electroconvulsive therapy ; mect mect Modified electroconvulsive therapy in dementia with Lewy bodies with drug - resistant psychiatric
第 10 章大脳皮質基底核変性症 337 第 10 章大脳皮質基底核変性症 CQ 10-1 大脳皮質基底核変性症 corticobasal degeneration(cbd) の認知症症状とその検査法は 推奨 CBD では認知症がしばしばみられる. 認知症に至る前に遂行機能, 視空間機能, 記憶等の
第 10 章大脳皮質基底核変性症 337 第 10 章大脳皮質基底核変性症 CQ 10-1 大脳皮質基底核変性症 corticobasal degeneration(cbd) の認知症症状とその検査法は 推奨 CBD では認知症がしばしばみられる. 認知症に至る前に遂行機能, 視空間機能, 記憶等の低下が指摘されており, これらの機能を評価する必要がある ( グレードなし ). 背景 目的 CBD
Vol.0 No. 0 図 Montreal Cognitive AssessmentMoCA orientation visuospatial attention orientation 4 visuospatial executive MMSE MoCA language language me
Parkinson 病の認知機能障害を MMSE と MoCA により評価した多施設共同研究 : 慶應 PD データベース Cognitive impairment in Parkinson s disease patients evaluated by the Montreal Cognitive Assessment and the Mini-Mental State Examination.
_02.indd
30, 11-16, 2010 Z Z score Computed tomography ROC analysis 3 CT 1,2 CT 1/3 3 5 CT CT 6 7,8 MCA ASPECTS Alberta Stroke Programme Early CT Score 4 10 CT ASPECTS 50% 9 Z 10 CT Z CT 10 Z Z Z receiver operating
認知症診療ガイドライン2017_200_第2章.indd
2 behavioral and psychological symptoms of dementia BPSD BPSD BPSD 18 2 2 1,2 1 CQ 2 1 1. 2. frontotemporal lobar degeneration FTLD 3. 3 a. CQ 2 1 19 1 1 Alzheimer Lewy Alzheimer Alzheimer Lewy Alzheimer
評論・社会科学 ８５号（よこ）（Ｐ）／３．佐分
well-being well-being well-being well-being QOL well-being satisfaction appraisal 69 well-being 2025 520 http : //www.mhlw.go.jp/ 2000 2004 2005 well-being 1 Walker 1996 ; Picot 1997 2003 2004 Zarit 1980
E Societe de Pathologie Infectieuse de Langue Francaise (, 1991) E Spanish Thoracic Society (1992) E American Thoracic Society (ATS : 1993. ü ù2001 ) E British Thoracic Society (1993, ü è2001 ) E Canadian
1_2.eps
第32回 日本頭頸部癌学会ランチョンセミナー6 Pre-Meeting Abstract FDG-PET の頭頸部癌における臨床的有用性 司会 長 放射線治療センター長 講演 1 耳鼻咽喉科 部長 講演 2 PETセンター長 岡村 光英 先生 日時 2008年6月13日 金 12:00 13:00 会場 ハイアットリージェンシー東京 共催 第32回 日本頭頸部癌学会 日本メジフィジックス株式会社 136-0075
36(298) 35 3 a) Lund & Manchester Group の分類 (1994) 前頭側頭葉変性症 (FTLD) 1 前頭側頭型認知症 (FTD) 2 進行性非流暢性失語 (PNFA) 3 意味認知症 (SD) b) 臨床分類 (Karageorgiou & Miller 201
2015 9 30 (297)35 シンポジウム Ⅳ: 認知症の言語症状を徹底的に討論する 進行性非流暢性失語の症候と経過 大槻美佳 * 要旨 : 進行性非流暢性失語 (PNFA/nfvPPA)24 例を対象に, 神経学的所見, 神経心理学的所見, 画像所見, および経過を検討した その結果, 少なくとも 3 群に分類された 1 前頭葉性失語型 ( 古典的失語症分類ではブローカ失語, 超皮質性運動失語に該当する言語症状を呈する群
3) Balas. C. Michele, Happ. B. Beth, Yang. Wei et al: Outcomes associated with delirium in older patients in surgical ICUs, Chest, vol.135 (1), 18-25, 2009 4) Ban Thomas; Chronic disease and depression
臨床神経学雑誌第48巻第9号
TDP-43 β Table1 Classificationofmotorneurondiseases(motorneurondiseaseofbroad sense) I I I IV ALS(motorneurondiseaseofnarrow sense) 1 SporadicALS Classictype Progressivebulbarpalsy(PBP)type Progressivemuscularatrophy(PMA)type
et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology
37 Recommendations for the Management of Moyamoya Disease A Statement from Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) Research on intractable diseases of the
Vol.21 No AD Japanese-ADNI J-ADNI 2015 AMED AD NA-ADNI 400 AD AD 2. NA-ADNI 研究の主な成果 NA-ADNI 2004 NA-ADNI ADNI, ADNI-GO ADNI-2 phase
アルツハイマー型認知症のバイオマーカーの現状と課題 Biochemical biomarkers for Alzheimer s disease: present status and awaiting solution 京都府立医科大学分子脳病態解析学 / 教授 * 1. はじめに 460 65 10 1 85 3 1 Alzheimer s disease AD 5 7 2500 AD 460
慢性膵炎
- - 121 , g CCK g g - kgkcal kgkcal - g,,, - G.I.Res ; 10 : - ; 13 : - ; 22 : - Meier RF, Beglinger C. Nutrition in pancreatic diseases. Best Pract Res Clin Gastroenterol ; 20 : - Pfutzer RH, Schneider
21-07_後藤論文.smd
2015; 21: 5866 Yoichi Goto: Current status and future perspective of cardiac rehabilitation in Japan. J Jpn Coron Assoc 2015; 21: 5866 I 1 1 3 1 2 3 QOL 2 Fig. 1 1 196070 AMI AMI 1980 AMI CABG comprehensive
1 4 1 13 1 4 6 7 2012 7 27 12 50 13 40 1 7 27 13 40 14 30 1 7 28 13 20 14 10 1 Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode Charles L. Bowden
354 AD Functional Assessment Staging FAST 5) FAST 3 4) VaD AD 4) 4) DLB ) 7) 4) FTD BPSD 4,8) Behavioral and Psychological Symptoms of
2012 353 369 Medical Welfare for the Elderly with Dementia 1 Yumiko OKUMURA 2025 323 1) 1 1 1 3 3 1 2 3 3 2 alzheimer type dementia ATD dementia with Lewy bodies DLB fronto-temporal dementia FTD vascular
学 位 論 文 Doctoral Thesis 論 文 名 : 進 行 性 核 上 性 麻 痺 の 精 神 症 状 行 動 障 害 (Psychiatric and behavioral symptoms in progressive supranuclear palsy) 著 者 名 : 矢 田
熊 本 大 学 学 術 リポジトリ Kumamoto University Repositor Title 進 行 性 核 上 性 麻 痺 の 精 神 症 状 行 動 障 害 Author(s) 矢 田 部, 裕 介 Citation Issue date 2011-03-25 Type URL Thesis or Dissertation http://hdl.handle.net/2298/21682
若年認知症支援ハンドブック_H19
64 18 18 19 203 50 65 1) - 1 - 18 64 40 64 65 18 3064 10 54 4564 98 35 15 18 2) 45 64 10 6781 3) 1996 10 32 25600 34 10 70008000 4, 5) 10 5) 30 5 2 2) 58 42 2) 2:1 4) - 2 - 1 24, 6) Harvey 3064 185
Ⅱ Ⅲ Ⅳ Assertive community treatment - Issues from scientific and clinical literature with implications for practice The Impact of Supported Employment and Working on Clinical and
<91E63989F182A482C295618A7789EF8FB4985E8F575F E696E6464>
1 4 1 13 1 4 6 7 2012 7 27 12 50 13 40 1 7 27 13 40 14 30 1 7 28 13 20 14 10 1 Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode Charles L. Bowden
本文／宮川充司先生
Journal of the School of Education, Sugiyama Jogakuen University 7 65 78 2014 Article DSM-5, Revised Diagnostic Criteria by American Psychiatric Association : Neurodevelopmental Disorders, Intellectual
3) Clark T, Feehan C, Tinline C, Vostanis P. Autistic symptoms in children with attention deficit-hyperactivity disorder. Eur Child Adolesc Psychiatry 1999; 8: 50-5. 4) Howlin P, Asgharian A. The diagnosis
PubMed 1. CD-ROM MEDLINE MeSH PubMed 2. Automatic Term Mapping MeSH 3. Related Article 1 1. 2. MeSH Browser MeSH PreMEDLINE MeSH -2-
PubMed MEDLINE NLM 1879 Index Medicus 1960 MEDLARS Medical Literature Analysis and Retrieval System 1970 MEDLINE MEDlars online 1966 70 4,000 170 PubMed MEDLINE NLM National Center for Biotechnology Information
ren
51 * 1 1 IT 24 2010 NHK 2010 7.14 1960 1.08 OECD 2 5 1 2011 4 World Association of Sleep Medicine WASM 3 18 World Sleep Day 2011 11 30 no. 22730552 9 3 1 4,000 5,000 1998 4 4.4 3.3 Matsuda, 2011 Cognitive
<30332D D8CB492982D FC95E490E690B62D8FAC8FBC96BE90E690B62E706466>
A questionnaire survey on the use of placebo in clinical practice by nurses in Japan 1 1 2 2 1 4 1964 5, 6 1998 GCP 1 School of Nursing, Faculty of Medicine, Toho University 2Faculty of Medical Technology,
untitled
19 CSPOR CRC/2009.8.8-9 2009 8 8 ( ) - CSPOR CRC SEMINAR- twatanab@oncoloplan.com http://www.oncoloplan.com - Toru Watanabe MD - 2 Phase I: Dose Finding trial Phase II : Efficacy and Safety trial Phase
470 Dementia Japan Vol. 24 No. 4 December 2010 Freyne A et al., 1999, Sampson E et al., 2004 目的 方法と対象 , ,
Dementia Japan 24 : 469-478, 2010 469 原著 要旨 65 early - onset dementia : EOD EOD EOD 2,626 Epidemiology of Early - Onset Dementia in Ehime Tetsuo Kashibayashi 1,2, Tomohisa Ishikawa 3, Kenjiro Komori 2,
untitled
CONTENTS 01 02-03 04-05 06-07 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 48-49 50-51 52 01 02 Mishima,Michiaki 03 04 05 06 07 09 10 11
1 見出し1，12ポ，日本語ゴシック，英語Arial，段落後は6ポの設定です
8. Page1 8. B 1 5) 6) 2099 2370 50 400 mg 19 (1) 1) (a) 78.9% 30/38 4 3 35.7% 5/14 71.4% 10/1485.7% 12/142 1 83.3% 5/63 2 1 1 1 8. Page2 (b) 2099 1897 82.4% 1562/1897 2 84.0% 1298/1545 3 2 80.4% 472/58779.0%
特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書（案）
VOL.51 NO.6 JUNE 2003 JUNE 2003 9) Niederman MS et al: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention.
2009年133巻3号3月号.indb
Folia Pharmacol. Jpn.133 1 2 Chiroscience UCB S RR-..% AA C IC C/A A/ A R- II/ III II/III Chiroscience UCB S 1 - E-mail: koji_taya@maruishi-pharm.co.jp Author: Koji Taya, Satoshi Shimizu Title: Levobupivacaine
_’£”R‡Ù‡©
29 31 38 2008 31 1) 2) 2) 3) 2) 1) 2008 302008 12 Activities of Daily Living ADL ADL 42 ADL ADL 1990 QOL Quality of Life QOL 1 QOL // 2 Activity of Daily Living ADL Performance Status PS ADL 3 1) 2) 3)
DocHdl1OnPRS1tmpTarget
2015; 26 6 : 658-668 自己免疫性出血病 FXIII/13 診断ガイド Guidance on Diagnostic Criteria for Autoimmune Hemorrhaphilia FXIII/13(AHFXIII/13) FXIII/13 659 Contents 1 660 2 660 3 660 4 661 5 661 6 661 7 661 8 661 9 662
精神障害者
13 ACT 156-8585 2-1-8 TEL03-3304-5701 14 10 30 ACTassertive community treatment 1 ACT ACT ACT ACT Fidelity ScaleACT ACT ACT ACT ACT Fidelity 2000, 2001; 1994 Tessler & Gamache 2000 14 1 2002 1986 1994
.K.C.h...C...ren
4 quality of life QOL QOL QOL 3 QOL 19 mmhg 16 mmhg 14 mmhg 1 2 7 20 30 QOL QOL QOL QOL QOL QOL QOL 4 1 1 1 2 1 2 3 1 2 4 2 2 1 2 2 2 2 1 2 3 QOL 3 2 1 1 5 1 1 2 1 Abraham Wise 1 Nd YAG 2 1 200 500 200
Ⅰ診断 症候 鑑別診断 認知機能に関する訴え 正常ではなく認知症でもない 認知機能の低下あり 日常生活機能は正常 Amnestic n-amnestic 認知障害は記憶障害のみ 認知障害は１領域に限られる Amnestic Single 図1 表1 記憶障害 Amnestic Multiple n
1) 認知症 1 軽度認知障害 () とはどのような状態でしょうか? の診断基準を教えてください. 1 概要 Mild Cognitive Impairment() とは本来 Alzheimer 病 (AD) など認知症とはいえないが, 知的に正常ともいえない状態を指す. 最近ではおおよそ AD の前駆状態を意味する用語と捉える人が多い. このような状態が注目される背景には, 新治療薬開発により AD
EBM Reviews Ovid Ovid EBM Reviews ACP Journal Club Cochrane Database of Systematic Revie
EBM Reviews 2006 4 Ovid http://www.usaco.co.jp/products/ovid/ovidplatform.html Ovid EBM Reviews ACP Journal Club Cochrane Database of Systematic Reviews CDSR Database of Abstracts of Reviews of Effectiveness
老年医学update2007-08
Geriatric Medicine Update 2007-08 (ISBN978-4-7583-0298-2 C3002) Editor: Journal Publication Committee, The Japan Geriatrics Society 2007. 7. 1 1st ed MEDICAL VIEW, 2007 Printed and Bound in Japan Medical
CQ 1,.,,.,,...,,,,,,.,,,,,,,MAO 2., 24,. A
CQ 1,.,,.,,...,,,,,,.,,,,,,,MAO 2., 24,. A 15 180 306 7,000 1 3 mg 103 92 89.3 60 60 100 173 28 16.2 3.52.92.3 1.7 1.7 1.7 2 64 78 80 3 ST 4 5 32 6 18 65 CQ 1 307 1 7,000 2006 ; 94 11 : 2149-2168. 2 2010
食道がん化学放射線療法後のsalvage手術
2006 2 17 52 Daly JM, et al. J Am Coll Surg 2000;190:562-573 Esophageal Cancer: Results of an American College of Surgeons Patient Care Evaluation Study Daly JM, et al. J Am Coll Surg 2000;190:562-573
56: 巻 3 号 (2016:3) 1968 年,Rebeiz らは, 進行性の左右非対称な筋強剛と失行に加え, 皮質性感覚障害,alien limb sign, ミオクローヌス, ジストニアを認める 3 症例を報告した 1). 病理学的には大脳皮質, 黒質, 小脳歯状核の変性と, 胞
56:149 1 * 2 1 大脳皮質基底核症候群, 大脳皮質基底核変性症, 診断基準,Armstrong 基準, タウオパチー 大脳皮質基底核変性症 (corticobasal degeneration; CBD) は, 大脳皮質と皮質下神経核 ( とくに黒質と淡蒼球 ) の神経細胞 が脱落し, 神経細胞およびグリア細胞に異常リン酸化タウが 蓄積する 4 リピート タウオパチーである. 近年,CBD
imazu.org
2013 9 1512:00~13:00 2F http:// imazu.org 5 1 68 19 54 127 14 17 100 31 http:// imazu.org 1 55 200X S 201X http:// imazu.org 1 55 http:// imazu.org 1 55 http:// imazu.org 75mg/ 1 9g / 21 mg 70 % 14.7 mg
終末期の呼吸困難症状への対応*松坂最終修正
Clinical Question 2017 5 27 1 PCOC 1. 12778 ( 55%, 45% NRS. 1 54, 35%. NRS. NRS,,,,,,,, Performance status, Ekstrom, M., et al.2016 J Pain Symptom Manage 51(5):816-23. . 1 85 ADL. 3,,,,. JCS200,, 40 /,
..
A general framework of interventional study in cognitive rehabilitation for the elderly. YOSHIDA Hajime, OOKAWA Ichiro and TUCHIDA Noriaki The present article describes the general framework of our interventional
56-2.ren
2006.5.1 200656 2,127-139 JSAM JSAM KAMS KOMS) JSAM) KOMS JSAM,, 629-0392 Kawakita Kenji, Department of Physiology, Meiji University of Oriental Medicine, Hiyoshi-cho, Nantan City, Kyoto, Japan 629-03
Systematic Review of Psychological Assessment for elder clients, No. The review about Intelligence or Memory Scale for Dementia Kyoko WATANABE
Systematic Review of Psychological Assessment for elder clients, No. The review about Intelligence or Memory Scale for Dementia Kyoko WATANABE http://www.stat. go.jp. % Mini Mental State Examination MMSE
不安障害研究, 9(1), 17-32, 2017
9(1), 17 32, 2017 Panic and Agoraphobia Scale 1 2 3 2 2 2 2 4 4 1 2 3 4 Panic and Agoraphobia Scale PAS DSM-IV-TR APA, 2000 3 4 PAS PAS PAS Patient Global Impression Improvement PAS 1980 Diagnostic and
C/NC : committed/noncommitted
C/NC : committed/noncommitted 110 time post-icd implant 1) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators Preliminary report : Effect of encainaide and flecainide on mortality in a
) 5 Lawton QOL 4 4 QOL Lawton 4) Philadelphia Geriatric Center Affect Rating ScaleARS ARS QOL 5) HDS R
Vol. 12 No. 2 2002 389 397 Λ1 Λ2 16 10 30 1 2 Lawton Philadelphia Geriatric Center Affect Rating ScaleARS Lawton ARS + ARS 6 2 ARS 2 12:00 15:0017:00 11:30 16:00 1 2 ARS 1 2 ARS QOL QOL QOL 1) QOL QOL
untitled
The Sense of Burden of Mother with Severely Disabled Children at Home and the Related Factors Noriko Kuno Keiko Yamaguchi Chieko Morita Key Words sense of burden, severely disabled children, mother,, Luescher
4703ALL01
473201010 *** (1999) 16 2017 20023 2 1 2 1220 (1999a),(1999b) (1998), (2002) (2003)(1999)(2003) Conjoint Analysis Conjoint Analysis Willingness to PayStandard gamble Time trade-off Rating Scale Willingness
縺ｻ繧
49 2015. 1 1 1 2 3 1 2 3 1 FAD : Female Athlete Triad 1, 2 3 FAD 4 57 1020 2030 24 9 8 9 10 1113 6 6 14 15 1 2 1 2012 5 6 1 245 211 86.1 24 2 1 4 7 2 3 SPSS Ver.20 χ 2 5 3 1 1 19.6 18 20.651 19 20.651
SBP hospitalist network.key
1 Treatment and Prophylaxis of Spontaneous Bacterial Peritonitis (1); (2), (3). (1) (2) (3) :, :, 2 Clinical Question 1 72...,.,,.,... 3. CT..,. 4? SBP? SBP. 5 Clinical Question SBP? SBP,? 6 SBP (Spontaneous
1 6 1 3 1 4 4 6 11 13 30 14 10 1 6 11 14 10 15 00 1 6 12 13 10 14 00 1 A novel psychotherapeutic intervention for treatment resistant depression and suicidal behaviour at the Life Promotion Clinic: Emotion
IPSJ SIG Technical Report Vol.2010-HCI-139 No /7/ , Toward the Development of a Music Therapy System that Prompts Elderly Peo
1 1 2 3, 4 5 2 1 1 Toward the Development of a Music Therapy System that Prompts Elderly People to Sing with Accompaniment. Chika Oshima, 1 Koichi Nakayama, 2 Kiyoshi Yasuda, 4 Kazushi Nishimoto 5 and
13122052_14山口.indd
108 Dementia Japan 28 : 108-115, 2014 原 著 要 旨 Key Words : 44 79.8±6.7 MMSE 1 : 44 16 4 20 11 28 47.87±27.0 16.2±3.5 mg 21 18 mg 2 : 5 MMSE 20 18.0±6.6 26.1±19.9 20.2±6.2 p=0.022 3 5 Rivastigmine transdermal
intent-to-treat population, which included all patients who received at least 1 dose of medication at baseline and had at least 1 postbaseline assessm
BPSD に対する抑肝散の効果 (140828) 抑肝散に関する RCT が結構たくさん出ている 実際 BPSD に関しては効果を実感する症例も あると思う いくつかの論文を読んでみた PECO P:BPSD in elderly patients with dementia(ninety inpatients with dementia according to the Diagnostic and
untitled
2008/04/27 1. 1 2 staticdynamics etc 3 Hedberg A, Carlberg EB, Forssberg H, Hadders-Algra M. Development of postural adjustments in sitting position during the first half year of life. Dev Med Child Neurol.
Special IssueDiagnoses and therapeutic agents for age-related diseases Reviews Original Case reports β Medicinal drugs affecting on clinical laboratory blood test results and adverse effects of them
財団法人 在宅医療助成 勇美記念財団
( 財 ) 在宅医療助成勇美記念財団 2009( 平成 21) 年度在宅医療助成完了報告書 軽度認知障害 (MCI) における Quality of Life(QOL) の特徴と関連要因について 申請者名 : 辰巳寛所属機関 : 愛知学院大学心身科学部職名 ; 講師所属機関所在地 : 愛知県日進市岩崎町阿良池 12 提出年月日 : 平成 22 年 8 月 27 日 共同研究者 : 山本正彦 ( 愛知学院大学心身科学部
認知症診療 実践ハンドブック
Ⅰ. 認知症 軽度認知障害の診断 治療へのアプローチ 1 認知症の症候, 検査, 診断 1 認知症の症候, 検査, 診断 1 認知症 軽度認知障害の概念, 実態, 診断への道筋 A 認知症 軽度認知障害とは? 1. 認知症の概念と診断基準認知症とは一度正常に発達した認知機能が後天的な脳の障害によって持続的に低下し, 日常生活や社会生活に支障をきたすようになった状態を指す. 診断基準として, 世界保健機関による国際疾病分類第
VOL. 21 NO. 2 CHEMOTHERAPY 395
394 CHEMOTHERAPY MAR. 1973 VOL. 21 NO. 2 CHEMOTHERAPY 395 396 CHEMOTHERAPY MAR. 1973 VOL. 21 NO. 2 CHEMOTHERAPY 397 398 CHEMOTHERAPY MAR. 1973 VOL. 2 1 NO. 2 CHEMOTHERAPY 399 400 CHEMOTHERAPY MAR. 1973
untitled
239 10 3 14 00 14 50 1 : 10 2 10 30 11 30 1 : 10 4 13 00 14 00 1 : 10 2 13 00 14 00 1 : Peter St. George - Hyslop University of Toronto 10 2 14 10 15 10 1 : Randall Bateman Neurology at Washington University
flF™m…−…n„Efic’æ’¶
44 2006 Cognitive Rehabilitation by means of Personal Computer for Cerebrovascular Disease Patients with Attentional Disorders 1 1 2 2 5 4 1 PC ABA design 4 PASATTMT Ponsford PC SAS working memoryattention
臨床神経学雑誌第49巻第5号
Alzheimers β Table1 NeuropathologicalclassificationofFTLD 1.Tauopathy(withassociatedneuronlossandgliosis)andinsolubletauwithapredominanceof3Rtau,themostlikely diagnosesare: FTLD withpickbodies a) FTLD
認知症診療ガイドライン2017_1600_第16章.indd
16 CQ 16 1 B 1 Wernicke Wernicke Korsakoff B 12 B 12 D B 1 3 1 Wernicke 3 Caine 1 2 3 4 2 Wernicke 2 3,4 Wernicke 85% Korsakoff 4 B 6 B 12 B 12 5 Shorvon B 12 B 12 2 6 7 4D derma titis diarrhea dementia
2
27 年 度 精 神 保 健 福 祉 基 礎 研 修 会 1 2 350 300 303 323 250 200 150 100 50 218 218 173 136 119 212 204 258 228 247 237 147 142 152 137 137 127 128 134 107 91 86 81 11 14 17 20 3 4 350 300 250 200 150 4.7 3.8
...l.....w.G..
The Study of Quality of Life Evaluation in which SF-36 was used in Brain Tumor Patients subscale PF Physical Functioning RP Role PhysicalGH General healthsf Social FunctioningRE Role Emotional BP Bodily
Power Transformation and Its Modifications Toshimitsu HAMASAKI, Tatsuya ISOMURA, Megu OHTAKI and Masashi GOTO Key words : identity transformation, pow
Power Transformation and Its Modifications Toshimitsu HAMASAKI, Tatsuya ISOMURA, Megu OHTAKI and Masashi GOTO Key words : identity transformation, power-normal distribution, structured data, unstructured
66-1 田中健吾・松浦紗織.pwd
Abstract The aim of this study was to investigate the characteristics of a psychological stress reaction scale for home caregivers, using Item Response Theory IRT. Participants consisted of 337 home caregivers
Valganciclovir 1 CMV valganciclovir VGCV CMV IgM CMV-DNA CMV 34 VGCV 2 1 CMV CMV ganciclovir valganciclovir MRI cytomegaloviru
2012445559 55 Valganciclovir 1 CMVvalganciclovirVGCV 1 21 5 CMV IgM CMV-DNA CMV 34 VGCV 2 1 CMV CMV ganciclovirvalganciclovir MRI cytomegalovirus; CMV TORCH CMV 1 CMV valganciclovirvgcv 21 2 1 1 2 23 37
橡
TP T-13i AST ALT ALP Y CTP LOH CHE CRP 8.7 id 0.4 mg/d 21 AWL 131U/L 257 LU/L 12 111/L 234 11J/L 344 IU/L 0.30 mid No K a BUN ORE UA 142 meq/1 4.3 meqa 108 meqa 15.8 met! 0.71 mg/di 5.0 mg/d CEA 5_5 n8/m1
7) G. N., A. A. Sondore et al.: The Use of Hyperbaric Oxygenation in Intensive Therapy of Patients with Liver Damage. VI Int. Cong. HBO Medicine, Moscow, Sept 2 `6:341, 1981 8) J. J. Moder, M. D.: Phagocytic
<93C195CA D834F E696E6464>
45 I I Diabetes and Heart: Insight by Imaging Juhani Knuuti Turku PET Centre, Turku University Central Hospital II I Development and Application of Beta-Amyloid Imaging Agents Chet A. Mathis Department
第4回企画展 わたしたちの脳
"The Wisdom of the Body" The Structure of Brain Peripheral Nervous System Localization of Brain Function Homeostasis The Brain Difference between Humans and Other Mammals The history of brain research
REM Rapid Eye Movement REM Zzz Non-REM
Sleep and sleep-related disorders in the elderly 20051027 REM Rapid Eye Movement REM Zzz Non-REM 90 180 270 360 90 How old is the elderly in sleep? 40 In: Primer of Polysomnography Circadian rhythm 24
日本皮膚科学会雑誌第122巻第2号
J Dermatol Sci Vitam Horm NEnglJMed Lancet J Clin Invest Antitoxid Redox Signal Diabetes Metab Res Rev Diabetes Care Diabet Med Diabetes care Diabetes Care J Foot Ankle Surg Wound Repair Regen Lancet Foot
PET n = 7 AD n = 20 図 3 PiB AD A 3. わが国のアミロイド PET の現状 PET 100 PiB 15 BF 図 4 J-ADI 105 図 5 20%MCI 60% AD 90% MCI AD AD E ApoE 4 AD 4 図 6 4.
病態理解と薬剤開発におけるアミロイド PET 検査の現状 Current Status of Amyloid PET in Pathophysiological Research and Drug Development for Alzheimer s Disease 東京都健康長寿医療センター研究所附属診療所 / 所長 * 1. はじめに PET A A AD 図 1 AD AD PET 2. アミロイド
164 SDD & SOD SDD E100 mg 80 mg B500 mg 2 E 2 B 48 /59 81 SDD SOD 10 /63 16 RCT RCT 1992 Gastinne 15 ICU 445 SDD E100 mg 80 mg B 10
163 特 集 SDD & SOD SDD(Selective digestive decontamination),sod(selective oropharynx decontamination), 腸内細菌叢, 耐性菌 Ⅰ はじめに SDD Selective digestive decontamination SOD Selective oropharynx decontamination
本文.indd
CQ ACC/AHA PECO PatientExposure Comparison OutcomePECO low-density lipoprotein cholesterol LDL C cholesterol cholesterol intensive OR agressive CQ target LDL C PubMed Systematic Reviews Clinical Study
表１‐４／表１‐４ 背幅４．０ミリ （３）Ｙ◎
６ ０ ８ 号 認 知 症 新 時 代 へ の 挑 戦 no.608 ク リ ニ シ ア ン ２ ０ １ ２年５月１日発行 年間１ ０回発行 発行 東京都文京区小石川４ ６ １ ０ vol.59 no.608 認知症 クリニシアン 発行人 直江 登 印刷 ひでじま 59巻4 5合併号 通巻608号 認知症新時代への挑戦 認知症新時代への挑戦 鳥取大学医学部 脳神経医科学講座脳神経内科学分野教授 中島健二
37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
日本職業・災害医学会会誌第51巻第5号
太田ら 同時多発性高血圧性脳葉出血の 1 手術例 図 1 搬入時 CT 上段 単純 CT 下段 造影 CT 図 2 術後の脳血管撮影検査では明らかな出血源は認めない 379 Reprint request: MULTIPLE SIMULTANEOUS HYPERTENSIVE LOBAR HEMORRHAGE Hirotsugu OHTA M.D. 1) and Akira YOKOTA M.D.
untitled
( ) - 1 - - 2 - 38% 26% A) Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma 124 (J Clin Oncol 7: 126-131, 1989) 124 95 29 II 1 2,000mg/m 2 x 4 8g/m